Monday, 25 June 2018 — Clinuvel Pharmaceuticals Ltd. today announced that it has completed the submission of a New Drug Application (NDA) for its drug Scenesse (afamelanotide 16 mg) as the first proposed therapy for patients with the rare metabolic…Original Article
Historic New Drug Application for the use of Scenesse (afamelanotide) in Rare Metabolic Disorder Erythropoietic Protoporphyria (EPP)
